Omarigliptin

Omarigliptin is an investigational long-acting inhibitor of dipeptidyl peptidase 4 (DPP4). The first DPP4 inhibitor to be clinically approved was sitagliptin. This has subsequently been joined by several more drugs such as vildagliptin, saxagliptin, linagliptin and alogliptin.

General

Type : Sulfur Compound, Gliptin, Pyrazole

Chemical_Nomenclature : (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine

Canonical SMILES : CS(=O)(=O)N1C=C2CN(CC2=N1)C3CC(C(OC3)C4=C(C=CC(=C4)F)F)N

InChI : InChI=1S\/C17H20F2N4O3S\/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19\/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3\/t12-,15+,17-\/m1\/s1

InChIKey : MKMPWKUAHLTIBJ-ISTRZQFTSA-N

Other name(s) : MK-3102  ||  MK3102  ||  UNII-CVP59Q4JE1  ||  CVP59Q4JE1


MW : 398.42

Formula : C17H20F2N4O3S

CAS_number : 1226781-44-7

PubChem : 46209133

UniChem : MKMPWKUAHLTIBJ-ISTRZQFTSA-N

IUPHAR : 8402

Wikipedia : Omarigliptin

Target

Families : Omarigliptin ligand of proteins in family
DPP4N_Peptidase_S9

Structure :
4PNZ

Protein :
human-DPP4

References (2)

Title : Omarigliptin inhibits brain cell ferroptosis after intracerebral hemorrhage - Zhang_2023_Sci.Rep_13_14339
Author(s) : Zhang Y , Liu Y , Yong VW , Xue M
Ref : Sci Rep , 13 :14339 , 2023
Abstract :
PubMedSearch : Zhang_2023_Sci.Rep_13_14339
PubMedID: 37658227

Title : Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes - Biftu_2014_J.Med.Chem_57_3205
Author(s) : Biftu T , Sinha-Roy R , Chen P , Qian X , Feng D , Kuethe JT , Scapin G , Gao YD , Yan Y , Krueger D , Bak A , Eiermann G , He J , Cox J , Hicks J , Lyons K , He H , Salituro G , Tong S , Patel S , Doss G , Petrov A , Wu J , Xu SS , Sewall C , Zhang X , Zhang B , Thornberry NA , Weber AE
Ref : Journal of Medicinal Chemistry , 57 :3205 , 2014
Abstract :
PubMedSearch : Biftu_2014_J.Med.Chem_57_3205
PubMedID: 24660890
Gene_locus related to this paper: human-DPP4